Viewing nowTemisil Tablets (Terbinafine Hydrochloride)
Terbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Samik Pharmaceutical Co., Ltd.

MFDS item code 200403413 · Notified 2004.11.16
Treatment of onychomycosis, dermatomycosis (such as tinea pedis and tinea corporis), and tinea capitis in children
This medication is effective for treating dermatophytosis caused by dermatophyte fungi such as athlete's foot, tinea corporis, and tinea cruris in adults. It is also used for treating tinea capitis in children. It helps improve the symptoms of fungal infections of the skin and nails.
Administer terbinafine at a dose of 125 mg twice daily or 250 mg once daily. The duration of administration according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital type, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Usually administer for 6 weeks~3 months. For infection of the fingernails or relatively small toenails, or in younger patients, the treatment period may be shortened to 3 months or less. Three months of treatment is usually sufficient for toenail infections, but some patients may require 6 months or longer. The treatment period may be longer in patients with slow nail growth. For patients with creatinine clearance less than 50 mL per minute, reduce the daily dose by 1/2.
Administer to children aged 2 years and older. Administration is not recommended for children under 2 years because there is no experience with its use. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly for an appropriately specified period. Body weight less than 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Because experience with treatment is limited, determine whether to administer after considering the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.
This drug is not recommended for patients with chronic liver disease or active liver disease. Before administration, liver function tests and a history of liver disease must be confirmed. If symptoms suggestive of liver dysfunction occur, inform your doctor immediately and ensure the condition is checked with a liver function test. This drug may affect liver function, so regular liver function tests should be performed within 4 to 6 weeks after starting treatment. If liver function tests show an increase, immediately stop taking the medication. Patients with blood disorders or severe renal failure, infants under 2 years old, and breastfeeding mothers should not take this drug. Patients with lactose intolerance or certain genetic disorders should avoid this drug due to the lactose content. Caution is advised for the elderly, patients with decreased renal function, and children weighing less than 20 kg. This drug may rarely cause severe skin reactions or liver failure; if such symptoms occur, immediately discontinue use and consult your doctor. Symptoms such as dizziness may occur when driving or operating machinery, so caution is needed. Interactions may occur with other medications, so inform your doctor or pharmacist about any other medications you are taking. Pregnant women or those who may become pregnant should carefully evaluate the benefits and risks before using this medication, and breastfeeding women are advised to discontinue breastfeeding. In the case of overdose, symptoms such as headache, nausea, dizziness may occur, and immediate medical attention should be sought. Keep this medication out of the reach of children and store it at room temperature away from direct sunlight.
Liver failure, hepatitis, bile duct obstruction, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, malaise, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, subcutaneous hemorrhage, leukopenia, anemia, rash, itching, photosensitivity reaction, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, vesicular dermatitis, psoriasis-like rash, exacerbation of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, elevated myoglobin, hypotension, dyspnea, chest tightness, urticaria, erythema, facial edema, lymphangiectasia, abdominal distension, decreased appetite, dyspepsia, nausea, mild abdominal pain, diarrhea, discomfort in the upper abdomen, thirst, vomiting, glossitis, depression, anxiety, headache, taste disorder, dizziness, drowsiness, sensory disturbances, decreased sensation, decreased attention, insomnia, elevated BUN, frequent urination, visual impairment, tinnitus, anaphylactic reaction, angioedema, superficial erythematous lupus, increased serum total cholesterol, increased triglycerides, malaise, tongue discoloration, palpitations, edema, abnormal menstruation, paralysis, systemic disorder, fever, fatigue, weight loss, anaphylaxis, serum sickness-like reaction, blurred vision, decreased visual acuity, hearing loss, auditory impairment, vasculitis, permanent loss of smell, hyposmia, drug rash with eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, elevated serum creatine phosphokinase, headache, nausea, upper abdominal pain, dizziness
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent air and moisture from entering. It is best to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature.
White to light yellow round tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowTerbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Samik Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
GP Therapeutics Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Hutex Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Anguk Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Medica Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Gyeongnam Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Daehwa Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.